

Iowa Department of Human Services

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization CYSTIC FIBROSIS AGENTS, ORAL

(PLEASE PRINT - ACCURACY IS IMPORTANT)

		•	,			
IA Medicaid Me	ember ID #	Patient name		DOB		
Patient address	s					
Provider NPI		Prescriber name		Phone		
Prescriber add	Fax					
Pharmacy nam	ne	Address		Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.						
Pharmacy NPI		Pharmacy fax	NDC			
	ation (PA) is required	d for oral cystic fibrosis age	nts. Payment will be c	onsidered for patients when		
1) Patient meets the FDA approved age; and						
2) Patient has a diagnosis of cystic fibrosis (CF); and						
3) Patient has a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene confirmed by an FDA-cleared CF mutation test (attach test results) for which the requested drug is indicated; and						
Prescriber is a CF specialist or pulmonologist; and						
5) Baseline liv	ver function tests (A	ST, ALT, and bilirubin) are ו	provided; and			
 Requests for Trikafta will not be considered for patients with severe hepatic impairment (Child-Pugh Class C); and 						
7) Will not be used with other CFTR modulator therapies.						
If the criteria for coverage are met, an initial authorization will be given for 6 months. Additional approvals will be granted if the following criteria are met:						
1) Adherence to oral cystic fibrosis therapy is confirmed; and						
Liver function tests (AST, ALT, and bilirubin) are assessed every 3 months during the first year of treatment and annually thereafter.						
Non-Preferre	<u>d</u>					
☐ Kalydeco	☐ Orkambi	☐ Symdeko ☐	Trikafta			
	Strength	Dosage Instructions	Quantity	Days Supply		
Diagnosis (Attach copy of FDA-cleared CF mutation test results):						
Attach copy of baseline liver function test (AST/ALT/bilirubin).						
Prescriber Specialty: ☐ CF Specialist ☐ Pulmonologist ☐ Other (specify):						

470-5627 (Rev 1/21) Page 1 of 2

Request for Prior Authorization CYSTIC FIBROSIS AGENTS, ORAL

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Will requested medication be used with other CFTR modulator therapies? ☐ No ☐ Yes					
Trifakta Requests:					
Does patient have severe hepatic impairment (Child-Pugh Class C)? ☐ No ☐ Yes					
Renewal Requests:					
Patient is adherent to oral cystic fibrosis therapy: Yes No					
Liver function tests (AST/ALT/bilirubin) are assessed every 3 months during first year of treatment and annually thereafter: Yes No Most recent lab date:					
Attach lab results and other documentation as necessary.					
Prescriber signature (Must match prescriber listed above.)	Date of submission				

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-5627 (Rev 1/21) Page 2 of 2